Understanding the Neurologic Impact of Chemotherapy, Complications and Cancer Therapies
-
Click here to listen to this article - Share via
Key Facts:
- Chemotherapy-induced neurotoxicity spans cognitive dysfunction (“chemo brain”), seizures, neuropathies, and encephalopathy.
- Mechanisms involve disruption of neural networks, altered hippocampal metabolism, and neuroinflammation, even without direct CNS involvement.
- Newer agents like immunotherapies, biologics, and checkpoint inhibitors introduce novel and complex neurologic complications.
- Combined modalities, such as chemotherapy plus radiation, often compound neurologic damage, requiring adjustments to treatment regimens.
- Early recognition and interdisciplinary collaboration between oncology and neurology are critical for managing these side effects.
We are getting better at extending survival. That’s the good news. The problem is that we are increasingly confronted with the neurologic price of that survival. The benefits of chemotherapy are real, but they are often shadowed by serious, lasting damage to the central and peripheral nervous systems. This isn’t a minor side effect.
These neurologic complications—from subtle cognitive impairment to profound neurotoxicity—are becoming a central concern for us and for our patients. Reactive oxygen species (ROS) production and inflammatory processes are involved in the pathogenesis of chemotherapy-induced neurotoxicity, further complicating the picture.
The “Why” Behind Chemotherapy Treatment and Adverse Effects
It’s probably helpful to back up. What is this chemotherapy treatment even doing?
At its core, chemotherapy drugs are basically poisons. But they’re designed to be selective poisons. The main idea is that cancer cells grow and divide like crazy, way faster than most normal cells. These anti-cancer drugs are built to find and destroy cancer cells that are in that process of dividing (the “cell cycle”). And they are good at it. They kill cancer cells and stop tumors from growing.
The real problem? Other cells in our bodies also grow fast.
Think about your hair follicles. Or the lining of your digestive tract. Or your bone marrow, which is constantly churning out new blood cells.
The chemotherapy treatment can’t always tell the difference between a dividing cancer cell and a dividing hair cell. So it hits them both. The mechanisms involved in nausea and vomiting associated with chemotherapy are complex and not fully understood, impacting the patient’s quality of life.
And that’s where the adverse effects come from. It’s why hair loss is so common. It’s the “why” behind chemotherapy-induced nausea and why it messes with your immune system. The drug is doing its job... just a little too well, hitting healthy cells right alongside the cancer.
This is the classic trade-off. We accept these side effects to treat cancer. But it turns out, the damage doesn’t always stop at hair and bone marrow.
The Neurologic Burden of Chemotherapy
This isn’t just one thing. Chemotherapy-related neurotoxicity manifests across a spectrum. Cognitive dysfunction. Seizures. Crippling neuropathies. Encephalopathy. White matter abnormalities. We’re seeing all of it.
This isn’t a new revelation, either. A foundational 2010 paper gave us a detailed overview of how these chemotherapeutic agents create structural and functional damage in the brain. It connected the dots from cellular disruptions to the clinical symptoms of “chemo brain” and those frightening encephalopathy syndromes [1].
But the field has moved. A 2020 review had to expand that scope significantly, bringing in the neurotoxicity caused by our newer tools—immunotherapies, biologics. The paper wasn’t just academic; it was a call for early recognition. For timely intervention. It underscored that we have to manage these neurologic complications if we want to talk about “patient outcomes” in a meaningful way [2].
Mechanisms of Chemotherapy-Related Cognitive Impairment
Let’s talk about “chemo brain.” It’s a term patients use, and frankly, it’s pretty accurate. It’s the memory lapses, the difficulty concentrating, the fog, the loss of executive function.
For a long time, the mechanisms were murky. But the picture is getting clearer. A 2025 systematic review pulled together imaging and neurophysiological data [7]. It’s not just “fog.” It’s quantifiable disruption of neural networks. It’s a breakdown in functional brain connectivity. And this is happening even in patients without direct central nervous system (CNS) involvement. The treatment itself is the culprit.
Animal models and human studies are backing this up. Look at the 2021 study on cisplatin and gemcitabine. Chronic administration was found to alter hippocampal metabolism. It reduces synaptic excitability. It induces neuroinflammation [5]. These aren’t vague concepts; these are measurable biological changes that map directly onto the cognitive symptoms our patients report.
RELATED: A Better Understanding of the Value of Functional Medicine, with Dr. Will Cole
Discover how CRISPR gene editing is creating personalized cancer therapies, enhancing immunotherapy, and offering new hope for hard-to-treat cancers.
Let’s Talk About Chemotherapy-Induced Peripheral Neuropathy (CIPN)
“Chemo brain” is one thing. But then there’s Chemotherapy-Induced Peripheral Neuropathy, or CIPN. And for many cancer survivors, this is the thing that sticks around.
This is that crippling neuropathic pain. The numbness, burning, or tingling in the hands and feet. It’s not just annoying—it’s a constant, painful reminder that can make it hard to button a shirt, walk, or even hold a pen. CIPN causes symptoms including pain, tingling, numbness, and sensitivity to cold, primarily beginning in the hands and feet.
It’s real, physical damage.
We’re finding that many chemotherapeutic drugs (especially ones used for breast cancer and colorectal cancer, like platinum-based drugs or taxanes) are just brutal on sensory neurons. They seem to attack the nerves themselves, particularly the dorsal root ganglia, which is like the command center for those neurons.
And the real kicker is that it’s often dose-dependent. The more treatment you get, the higher the risk. For some people, these persistent symptoms of peripheral neuropathy become a chronic disease they have to manage long after the cancer is gone. It’s one of the most significant neurotoxic effects we’re battling, and it’s a huge focus for clinical studies trying to find ways to prevent it. Acute symptoms of CIPN appear in the hours and days after drug infusion, while persistent symptoms occur in up to 68% of patients one month following completion of chemotherapy.
Peripheral and Central Neurologic Syndromes
Cognitive impairment is one piece. The other is the direct structural damage. We’re talking about damage to the CNS and the peripheral nerves.
A 2012 chapter in the Handbook of Clinical Neurology laid out the classic neurologic syndromes: encephalopathy, seizures, even spinal cord toxicity. These are the known risks associated with agents we use all the time, like methotrexate, ifosfamide, and cytarabine [8].
This is where imaging becomes indispensable. A 2006 overview highlighted how critical magnetic resonance imaging (MRI) has become. It’s not just for diagnosis; it’s for detection. It allows us to identify these chemotherapy-induced brain lesions, hopefully early, and to monitor them [4].
Newer Agents, Newer Challenges
And just as we started to get a handle on the “classic” toxicities, the entire treatment landscape shifted.
Cancer treatment is becoming more personalized. That means small-molecule inhibitors. It means immunotherapies. And it means novel risks. A 2018 paper in Neuro-Oncology was blunt: clinicians need to be vigilant [10]. We have to recognize the early signs of neurotoxicity from these modern therapies before the damage is irreversible.
A 2021 review in Current Neurology and Neuroscience Reports really focused this concern, especially around T-cell engaging therapies and checkpoint inhibitors [6]. These agents are powerful. They are also unpredictable. The review wasn’t just a summary; it was a plea for collaboration. This is no longer just an oncologist’s problem. We need neurologists in the loop, managing these complex cases from the start [6].
RELATED: How Bioengineering Is Shaping Targeted Cancer Immunotherapy and Drug Delivery
Radiation and Combined Modalities
Then there’s the compounding factor. Neurotoxicity is rarely from a single source. Many patients receive both chemotherapy and radiation.
A 2015 paper reviewed these combined effects [3]. It’s exactly what we’d expect: the neurologic damage is often worse. The discussion has now shifted to strategies for modifying treatment regimens. How do we balance efficacy against this long-term neurologic damage? It’s a constant, difficult calculation [3].
Future Directions: Toward Neuroprotective Oncology
So, what’s next? The logical step is developing neuroprotective strategies.
We aren’t there yet. Not really. Most of the emerging research is still at a more basic level. A 2025 paper in Molecular Cancer discussed the broader “cancer–nervous system crosstalk” [9]. The idea is that if we can understand the fundamental tumor-neural interactions, we might open new avenues. Avenues for therapies that can prevent the neurologic injury while still hitting the cancer.
But that’s still on the horizon.
RELATED: Galleri: The Multi-Cancer Early Detection Blood Test, Explained
From trial phases to personalized care, here’s how healthcare providers can navigate cancer clinical trials and guide patients to better outcomes.
Closing Thoughts
The neurologic impact of chemotherapy is no longer a secondary concern. It’s a primary issue in cancer survivorship. Chemotherapy-induced peripheral neuropathy (CIPN) is a prevalent and severe toxicity occurring in 30 to 40 percent of cancer patients undergoing chemotherapy.
Our therapies are more advanced. Our understanding of their side effects must keep pace. Right now, that doesn’t mean we have a magic bullet to prevent neurotoxicity. It means early recognition is everything. It means routine neurologic monitoring can’t be an afterthought. And it means that interdisciplinary collaboration isn’t just a nice idea—it’s the only way we’re going to mitigate the very real impact of neurotoxicity and preserve a quality of life for the patients we’re working so hard to save.
References
[1] Dietrich J. (2010). Chemotherapy associated central nervous system damage. Advances in experimental medicine and biology, 678, 77–85. https://doi.org/10.1007/978-1-4419-6306-2_11
[2] Santomasso B. D. (2020). Anticancer Drugs and the Nervous System. Continuum (Minneapolis, Minn.), 26(3), 732–764. https://doi.org/10.1212/CON.0000000000000873
[3] Nolan, C. P., & DeAngelis, L. M. (2015). Neurologic complications of chemotherapy and radiation therapy. Continuum (Minneapolis, Minn.), 21(2 Neuro-oncology), 429–451. https://doi.org/10.1212/01.CON.0000464179.81957.51
[4] Hildebrand J. (2006). Neurological complications of cancer chemotherapy. Current opinion in oncology, 18(4), 321–324. https://doi.org/10.1097/01.cco.0000228735.39885.3e
[5] Umfress, A., Speed, H. E., Tan, C., Ramezani, S., Birnbaum, S., Brekken, R. A., Sun, X., Plattner, F., Powell, C. M., & Bibb, J. A. (2021). Neuropathological Effects of Chemotherapeutic Drugs. ACS chemical neuroscience, 12(16), 3038–3048. https://doi.org/10.1021/acschemneuro.1c00338
[6] Lee E. Q. (2021). Neurologic Complications of Cancer Therapies. Current neurology and neuroscience reports, 21(12), 66. https://doi.org/10.1007/s11910-021-01151-w
[7] Leskinen, S., Alsalek, S., Galvez, R., Ononogbu-Uche, F. C., Shah, H. A., Vojnic, M., & D’Amico, R. S. (2025). Chemotherapy-Related Cognitive Impairment and Changes in Neural Network Dynamics: A Systematic Review. Neurology, 104(2), e210130. https://doi.org/10.1212/WNL.0000000000210130
[8] Newton H. B. (2012). Neurological complications of chemotherapy to the central nervous system. Handbook of clinical neurology, 105, 903–916. https://doi.org/10.1016/B978-0-444-53502-3.00031-8
[9] Huang, S., Zhu, J., Yu, L., Huang, Y., & Hu, Y. (2025). Cancer-nervous system crosstalk: from biological mechanism to therapeutic opportunities. Molecular cancer, 24(1), 133. https://doi.org/10.1186/s12943-025-02336-4
[10] Zukas, A. M., & Schiff, D. (2018). Neurological complications of new chemotherapy agents. Neuro-oncology, 20(1), 24–36. https://doi.org/10.1093/neuonc/nox115
